Paradigm Biopharmaceuticals Limited Stock
Equities
PAR
AU000000PAR5
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.285 AUD | 0.00% | -3.39% | -32.94% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 100M 156M |
---|---|---|---|---|---|
Net income 2024 * | -52M -81.29M | Net income 2025 * | 12M 18.76M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.59
x | P/E ratio 2025 * |
7.31
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.7% |
1 day | +3.51% | ||
1 week | +3.51% | ||
Current month | -14.49% | ||
1 month | -23.38% | ||
3 months | -18.06% | ||
6 months | -57.25% | ||
Current year | -30.59% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Rennie
CEO | Chief Executive Officer | - | 14-05-01 |
Abby Macnish
DFI | Director of Finance/CFO | - | 22-08-29 |
Jill Forrest
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Donna Skerrett
CTO | Chief Tech/Sci/R&D Officer | - | 19-08-31 |
Paul Rennie
CEO | Chief Executive Officer | - | 14-05-01 |
Amos Meltzer
BRD | Director/Board Member | 58 | 20-12-08 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 7 M€ | +0.11% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 0.285 | 0.00% | 481,103 |
24-04-18 | 0.285 | -5.00% | 323,740 |
24-04-17 | 0.3 | +7.14% | 351,921 |
24-04-16 | 0.28 | +1.82% | 540,749 |
24-04-15 | 0.275 | -3.51% | 962,263 |
Delayed Quote Australian S.E., April 19, 2024 at 01:58 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-30.59% | 64.41M | |
-1.82% | 41.35B | |
+44.25% | 40.38B | |
+2.56% | 39.05B | |
-12.11% | 26.67B | |
+3.09% | 24.07B | |
-24.16% | 18.36B | |
+22.12% | 11.6B | |
-3.74% | 11.68B | |
+7.75% | 11.15B |
- Stock Market
- Equities
- PAR Stock